Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study

Takahiro Aoki; Hiroyuki Takahashi; Shiro Tanaka; Norio Shiba; Daiichiro Hasegawa; Shotaro Iwamoto; Kiminori Terui; Hiroshi Moritake; Hideki Nakayama; Akira Shimada; Katsuyoshi Koh; Hiroaki Goto; Yoshiyuki Kosaka; Akiko M. Saito; Keizo Horibe; Akitoshi Kinoshita; Akio Tawa; Takashi Taga; Souichi Adachi; Daisuke Tomizawa

doi:10.1111/bjh.16656

Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study

Takahiro Aoki, Hiroyuki Takahashi, Shiro Tanaka, Norio Shiba, Daiichiro Hasegawa, Shotaro Iwamoto, Kiminori Terui, Hiroshi Moritake, Hideki Nakayama, Akira Shimada, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Akiko M. Saito, Keizo Horibe, Akitoshi Kinoshita, Akio Tawa, Takashi Taga, Souichi Adachi, Daisuke Tomizawa

University Hospital

Research output: Contribution to journal › Article

Abstract

The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.

Original language	English
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.16656
Publication status	Accepted/In press - 2020

Keywords

acute myeloid leukaemia
chemosensitivity
children
myelosuppression
neutropenia

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.16656

Fingerprint Dive into the research topics of 'Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study'. Together they form a unique fingerprint.

Cite this

Aoki, T., Takahashi, H., Tanaka, S., Shiba, N., Hasegawa, D., Iwamoto, S., Terui, K., Moritake, H., Nakayama, H., Shimada, A., Koh, K., Goto, H., Kosaka, Y., Saito, A. M., Horibe, K., Kinoshita, A., Tawa, A., Taga, T., Adachi, S., & Tomizawa, D. (Accepted/In press). Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. British Journal of Haematology. https://doi.org/10.1111/bjh.16656

Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. / Aoki, Takahiro; Takahashi, Hiroyuki; Tanaka, Shiro; Shiba, Norio; Hasegawa, Daiichiro; Iwamoto, Shotaro; Terui, Kiminori; Moritake, Hiroshi; Nakayama, Hideki; Shimada, Akira; Koh, Katsuyoshi; Goto, Hiroaki; Kosaka, Yoshiyuki; Saito, Akiko M.; Horibe, Keizo; Kinoshita, Akitoshi; Tawa, Akio; Taga, Takashi; Adachi, Souichi; Tomizawa, Daisuke.

In: British Journal of Haematology, 2020.

Research output: Contribution to journal › Article

Aoki, T, Takahashi, H, Tanaka, S, Shiba, N, Hasegawa, D, Iwamoto, S, Terui, K, Moritake, H, Nakayama, H, Shimada, A, Koh, K, Goto, H, Kosaka, Y, Saito, AM, Horibe, K, Kinoshita, A, Tawa, A, Taga, T, Adachi, S & Tomizawa, D 2020, 'Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study', British Journal of Haematology. https://doi.org/10.1111/bjh.16656

Aoki, Takahiro ; Takahashi, Hiroyuki ; Tanaka, Shiro ; Shiba, Norio ; Hasegawa, Daiichiro ; Iwamoto, Shotaro ; Terui, Kiminori ; Moritake, Hiroshi ; Nakayama, Hideki ; Shimada, Akira ; Koh, Katsuyoshi ; Goto, Hiroaki ; Kosaka, Yoshiyuki ; Saito, Akiko M. ; Horibe, Keizo ; Kinoshita, Akitoshi ; Tawa, Akio ; Taga, Takashi ; Adachi, Souichi ; Tomizawa, Daisuke. / Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. In: British Journal of Haematology. 2020.

@article{e708822d27a948939677c9299ebe3b54,

title = "Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study",

abstract = "The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.",

keywords = "acute myeloid leukaemia, chemosensitivity, children, myelosuppression, neutropenia",

author = "Takahiro Aoki and Hiroyuki Takahashi and Shiro Tanaka and Norio Shiba and Daiichiro Hasegawa and Shotaro Iwamoto and Kiminori Terui and Hiroshi Moritake and Hideki Nakayama and Akira Shimada and Katsuyoshi Koh and Hiroaki Goto and Yoshiyuki Kosaka and Saito, {Akiko M.} and Keizo Horibe and Akitoshi Kinoshita and Akio Tawa and Takashi Taga and Souichi Adachi and Daisuke Tomizawa",

year = "2020",

doi = "10.1111/bjh.16656",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study

AU - Aoki, Takahiro

AU - Takahashi, Hiroyuki

AU - Tanaka, Shiro

AU - Shiba, Norio

AU - Hasegawa, Daiichiro

AU - Iwamoto, Shotaro

AU - Terui, Kiminori

AU - Moritake, Hiroshi

AU - Nakayama, Hideki

AU - Shimada, Akira

AU - Koh, Katsuyoshi

AU - Goto, Hiroaki

AU - Kosaka, Yoshiyuki

AU - Saito, Akiko M.

AU - Horibe, Keizo

AU - Kinoshita, Akitoshi

AU - Tawa, Akio

AU - Taga, Takashi

AU - Adachi, Souichi

AU - Tomizawa, Daisuke

PY - 2020

Y1 - 2020

N2 - The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.

AB - The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.

KW - acute myeloid leukaemia

KW - chemosensitivity

KW - children

KW - myelosuppression

KW - neutropenia

UR - http://www.scopus.com/inward/record.url?scp=85084120573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084120573&partnerID=8YFLogxK

U2 - 10.1111/bjh.16656

DO - 10.1111/bjh.16656

M3 - Article

AN - SCOPUS:85084120573

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -